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EDITORIAL COMMENT

Reversing Heart Failure With a
Ventricular Anchoring Device
Another Hope for Myopathic Mitral Regurgitation*
J. Eduardo Rame, MD

H

eart failure due to left ventricular (LV) sys-

secondary mitral regurgitation (MR). The increase in

tolic dysfunction remains highly prevalent,

LV volumes allows for maintenance of stroke volume

progressive in natural history, and prob-

and, depending on the changes in myocardial stiff-

lematic for patients hoping to survive with a good

ness, could also maintain lower LV ﬁlling pressures.

quality of life. The anatomic and physiologic adapta-

However, LV dilatation comes with the bioenergetic

tions in response to myocardial injury with ensuing

cost of increasing wall stress and myocardial oxygen

LV dysfunction include neurohumoral activation of

consumption, along with the increasing risk of pul-

sympathetic and renin-angiotensin-aldosterone sys-

monary venous congestion due to secondary MR of

tems, along with counter-regulatory response of

myopathic origin. In the current era, device therapy

natriuretic peptide systems; metabolic shifts adapt-

for heart failure due to cardiomyopathic LV systolic

ing to increasing energetic demand; and LV chamber

dysfunction incorporates paradigms of resynchroni-

dilatation. We evolved to incorporate these adapta-

zation (cardiac resynchronization therapy), mechan-

tions to facilitate survival in the critical period of

ical unloading with ventricular assist devices, and

acute exposure to risk. However, at least 2 of these

aortic counterpulsation. All of these have been

adaptations—neurohumoral activation and LV dilata-

demonstrated to induce reverse remodeling of the LV

tion—become maladaptive over the longer term.

via multifaceted mechanisms, especially in the pa-

Indeed, we are conﬁdent from the positive results of

tients with a good clinical response (1–3).

many randomized clinical trials that blockade of

SEE PAGE 229

neurohumoral pathways improves heart failure, in
some instances achieving a high degree of myocardial

In this issue of JACC: Basic to Translational Science,

reverse remodeling, returning the LV cavity to near

it is in this context that the work by Saeed et al. (4)

normal end-systolic and end-diastolic dimensions.

should be considered. The soft robotic ventricular

Increasing end-systolic and end-diastolic LV dimensions

is

a

hallmark

of

progressive,

assist device (SRVAD) is a free wall to septal brace

car-

that effectively anchors the LV dimension while

diomyopathic failure, which is often accompanied by

actuating through an extrinsic force an increase in LV
ejection. By applying synchronized cyclic force
transmitted from the LV free wall to the interven-

*Editorials published in JACC: Basic to Translational Science reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Basic to Translational Science or the American College of Cardiology.
From the Center for Translational Medicine, Jefferson Heart Institute,
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. Dr.

tricular

septum,

the

device

provides

dynamic

external compression and diastolic phase recoil back
to the “relaxed” curved conﬁguration.
The preclinical data to investigate the effect of the

Rame has reported that he has no relationships relevant to the contents

SRVAD using an adult swine model of acute LV sys-

of this paper to disclose.

tolic dysfunction with secondary MR induced by

The author attests he is in compliance with human studies committees

intracoronary microsphere injections has demon-

and animal welfare regulations of the author’s institutions and Food and
Drug Administration guidelines, including patient consent where

strated elimination of the MR with signiﬁcant in-

appropriate. For more information, visit the JACC: Basic to Translational

crease in LV fractional shortening at 5 and 30 min, an

Science author instructions page.

increase in the median ejected stroke volume of 50%,
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and an increase in the LV developed pressure. With

effective, and what timing algorithms should be

the increased stroke volume, there is a signiﬁcant

considered to offset the septal to free wall delay?

decrease in LV end-diastolic and left atrial pressure.

Fifth, what is the potential for myocardial recovery

Finally,

electrocardiography-synchronized

with adjunctive heart failure therapies of this me-

augmentation of native pulsatile ﬂow results in an

chanical platform? If the device can safely be main-

increase in pulse pressure and surplus hemodynamic

tained in low-support or nonactuated mode, can

energy.

future

the

investigations

demonstrate

improved

Although Saeed et al. (4) clearly demonstrate the

contractility? Last, to target both clinical effective-

successful augmentation of LV output with reduction

ness and maximize myocardial recovery, is there a

of MR in this acute model, several questions remain.

range for LV end-diastolic dimension and the degree

First, what happens to the structure and function of

of MR that could be used to identify the patients who

the LV, in the intermediate to long-term phase? Saeed

could beneﬁt the most after implantation of this car-

et al. intend to incorporate built-in pressure sensors

diac support device? We know from the ACORN trial

and test the device in a chronic animal model, but the

(5) that the CorCap fabric mesh device (Acorn Car-

fundamental question of what physiologic changes

diovascular, St. Paul, Minnesota) that was surgically

will result from sustained actuation of a ventricular

implanted

anchoring and compression device remains prescient.

beneﬁted patients the most who had a LV end-

Second, what are the longitudinal changes in neuro-

diastolic dimension index in the range of 30 to

humoral activation within the acute, intermediate,

40 mm/m 2. If the chronic preclinical models provide

and long-term phases of this form of ventricular

variability in the degree of LV remodeling after

support? If we expect, as is the case with pericardial

myocardial injury, it would be important to look for

constriction, to have a net decrease in the myocardial

this phenotype of maximal treatment response to the

production and circulating levels of natriuretic pep-

SRVAD before translation toward clinical delivery.

for

circumferential

diastolic

support

tides, what should constitute the optimal neurohor-

Despite the need for clarity on these questions,

monal antagonist therapy to work synergistically with

which will enhance our grasp of the physiology

this mechanical paradigm of circulatory support?

relevant to this form of mechanically assisted heart

Third, what are the acute and chronic changes in right

failure, the work by Saeed et al. (4) has undoubt-

ventricular (RV) size and function, and the effects on

edly introduced the question whether a single de-

tricuspid regurgitation? Although we expect that a

vice paradigm can reverse myopathic MR while

decrease in MR and left atrial pressure will impact RV

sustaining ventricular output. Stay tuned. We can

afterload favorably, a critical question is: what effect,

only hope.

if any, will the actuation of the device have on the RV
free wall to septal dimension? We know from studying the effects of direct mechanical unloading with LV
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dyssynchronous heart failure, often accompanied by
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